Analysts expect NovaBay Pharmaceuticals, Inc. (NYSE:NBY) to post ($0.12) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for NovaBay Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.10). NovaBay Pharmaceuticals posted earnings of ($0.36) per share during the same quarter last year, which suggests a positive year over year growth rate of 66.7%. The business is scheduled to report its next earnings results on Thursday, August 10th.

According to Zacks, analysts expect that NovaBay Pharmaceuticals will report full year earnings of ($0.54) per share for the current year, with EPS estimates ranging from ($0.60) to ($0.47). For the next financial year, analysts anticipate that the business will report earnings of ($0.07) per share, with EPS estimates ranging from ($0.13) to ($0.02). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow NovaBay Pharmaceuticals.

NBY has been the topic of several analyst reports. Roth Capital set a $6.00 target price on NovaBay Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, June 20th. HC Wainwright set a $6.00 target price on NovaBay Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, March 26th. Laidlaw initiated coverage on NovaBay Pharmaceuticals in a report on Monday, March 27th. They issued a “buy” rating and a $10.00 target price on the stock. Maxim Group reiterated a “hold” rating on shares of NovaBay Pharmaceuticals in a report on Friday, March 24th. Finally, Zacks Investment Research upgraded NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 17th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. NovaBay Pharmaceuticals has an average rating of “Buy” and a consensus target price of $7.00.

NovaBay Pharmaceuticals (NBY) traded up 1.22% on Monday, reaching $4.15. 22,090 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $2.92 and its 200 day moving average is $3.51. NovaBay Pharmaceuticals has a 52 week low of $2.12 and a 52 week high of $5.29. The company’s market cap is $63.53 million.

COPYRIGHT VIOLATION WARNING: “-$0.12 Earnings Per Share Expected for NovaBay Pharmaceuticals, Inc. (NBY) This Quarter” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Get a free copy of the Zacks research report on NovaBay Pharmaceuticals (NBY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.